Comparison of Exenatide, Insulin or Pioglitazone on Glycaemic Control and β-cell Function in Drug-naive Type 2 Diabetic Patients: A Multicentre Randomized Parallel-group Trial

Trial Profile

Comparison of Exenatide, Insulin or Pioglitazone on Glycaemic Control and β-cell Function in Drug-naive Type 2 Diabetic Patients: A Multicentre Randomized Parallel-group Trial

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Exenatide (Primary) ; Insulin neutral protamine lispro/insulin lispro (Primary) ; Pioglitazone (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms CONFIDENCE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Aug 2015 Primary endpoint has been met. (Comparison Between Treatment Group (exenatide versus pioglitazone) of the Changes From Baseline in HbA1c at 48 Weeks), as per an article published in the Clinical Therapeutics.
    • 01 Aug 2015 Primary endpoint has not been met. (Comparison Between Treatment Group (exenatide versus insulin) of the Changes From Baseline in HbA1c at 48 Weeks), as per an article published in the Clinical Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top